Increased serum interleukin-6 level as a predictive biomarker for atrial fibrillation: A systematic review and meta-analysis
| Autor: | Peng Zhou, Maieryemu Waresi, Yikai Zhao, Hung-Chen Lin, Bangwei Wu, Nanqing Xiong, Huiyang Li, Qingyu Huang, Xinping Luo, Jian Li |
|---|---|
| Jazyk: | English<br />Portuguese |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Revista Portuguesa de Cardiologia, Vol 39, Iss 12, Pp 723-728 (2020) |
| Druh dokumentu: | article |
| ISSN: | 0870-2551 46089101 |
| DOI: | 10.1016/j.repc.2020.07.009 |
| Popis: | Background: Atrial fibrillation (AF) is related to a higher risk of thromboembolic events and mortality. Some studies have demonstrated that the inflammatory biomarker interleukin-6 (IL-6) is associated with a higher risk of higher thrombosis in AF patients, but the real effect of IL-6 remains a controversy. Methods: We conducted a systematic review and meta-analysis to investigate the association between IL-6 and thromboembolic events, as well as bleeding events, acute coronary syndrome (ACS) events and all-cause mortality in AF. Results: A total of five studies involving 22 928 patients met our inclusion criteria for the systematic review. The higher level of IL-6 in AF patients is related to long-term thromboembolic events including stroke (RR 1.44, CI 95% 1.09-1.90, p=0.01). IL-6 meant a higher risk of long-term bleeding risk (RR 1.36, CI 95% 1.06-1.74, p=0.02), ACS risk (RR 1.81, CI 95% 1.43-2.30, p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|